China Approves Lundbeck Antidepressant In Year-End Dash
Executive Summary
China FDA greenlights Lundbeck's Brintellix for severe depression, and more new drug approvals may be on the way. Physician education will be key for Brintellix, given relatively low number of psychiatrists in China.
You may also be interested in...
Generic Blow Looms For Lundbeck
With a new CEO taking the reins in September and a candidate entering the clinic for Parkinson’s disease, Lundbeck has opportunities for refreshment, both in the pipeline and the boardroom. But with generic competition battering down the company’s financial outlook, it may not be enough to bring the market along for the ride.
Vortioxetine Set For Japan Filing But Prospects Limited?
Positive results from a Japanese trial of Takeda/Lundbeck’s vortioxetine pave way for a planned approval filing in the country this year, but how might drug fare in the market?
Takeda's Deal Flurry Set To Wane
Takeda's reorganization and the focusing of its R&D on specialty medicines in three sectors is shifting to the next stage, with products moving through its pipeline; the company has lifted its financial outlook at the six-month stage, but is wary of the emergence of US generic competition to Velcade later this year.